A 9-Day Winning Streak Has Kymera Therapeutics Stock Up 17%
A nine-day run has added billions to the company’s value, but the underlying numbers present a complicated picture for investors.
A recent run in Kymera Therapeutics (KYMR) stock has added about $1.7 billion to the company’s market value. The move comes from a sustained advance, with the stock now moving higher for 9 consecutive trading days.
This streak produced a cumulative gain of 17%, bringing the company’s market value to about $12 billion. For shareholders, this extends a powerful trend: over the trailing twelve months, the stock has returned +188.2%.
How The Streak Stacks Up Against The S&P 500
- A 7-Day Winning Streak Has Boston Scientific Stock Up 8.6%
- 10 Green Days In A Row: Unity Software Stock Is Up 46%
- 7 Green Days In A Row: Everpure Stock Is Up 41%
- How Will Toll Brothers Stock React To Its Upcoming Earnings?
- How Will Keysight Technologies Stock React To Its Upcoming Earnings?
- How Will Home Depot Stock React To Its Upcoming Earnings?
Here is how KYMR stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | KYMR | S&P 500 |
|---|---|---|
| 1D | 2.6% | -0.2% |
| 9D (Current Streak) | 17.0% | 2.4% |
| 1M (21D) | 3.0% | 3.3% |
| 3M (63D) | 38.9% | 3.8% |
| YTD 2026 | 50.9% | 13.7% |
| 2025 | 93.4% | 16.4% |
| 2024 | 58.0% | 23.3% |
| 2023 | 2.0% | 24.2% |
Is this run supported by the business fundamentals?
The data presents a conflicting picture. On one hand, revenue growth is substantial, with sales over the last twelve months growing 134.8%. This is far ahead of the S&P 500 median revenue growth of 8.3%.
On the other hand, profitability is not part of the story. The company’s operating margin over the last twelve months is -329.8%, compared to an S&P 500 median of 18.4%. The market’s broader movement is not the driver here; while KYMR gained, the S&P 500 returned +2.4%. Sustained runs of this length are rare across the broader market: among large-cap benchmarks like the S&P 500, only a single stock is currently riding a winning streak of 9 days or more.
What is the disciplined way to think about this streak?
A long streak is information, not an instruction. It tells you that a stock has sustained momentum and is capturing the market’s attention. It does not, by itself, tell you whether the stock is a good or bad investment at its new price.
The disciplined move is to use the streak as a prompt to check your thesis. The core question for Kymera Therapeutics is whether its impressive growth justifies its significant operating losses. The recent price run makes that question more urgent for anyone holding or watching the stock.
A run like this is worth respecting, and worth testing: the momentum that lasts is usually the kind management itself is underwriting. Our Guidance Momentum screen tracks the stocks whose companies just raised their own forward numbers.
And for anyone who would rather back the theme than one company’s story, a biotech ETF like XBI holds the sector rather than this one name. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Streaks End. Discipline Compounds
A run like this is genuinely useful information: something about this business has the market’s full attention. But streaks are where discipline gets tested, because the urge to chase strength is strongest right before it pauses.
The Trefis High Quality (HQ) Portfolio channels that urge into a system: roughly 30 businesses selected for consistent cash generation, strong margins, and resilient balance sheets, sized and rebalanced with rules rather than excitement. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Enjoy the streak; own the process.